Thymagen vs Cortagen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
- Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed at the St. Petersburg Institute of Bioregulation as a cardioprotective and vascular bioregulator. It stimulates repair of cardiac and vascular tissue, with demonstrated benefits for coronary artery disease, atherosclerosis, and cardiac aging.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Short peptide half-life; gene regulatory effects persist beyond peptide clearance
- Admin Route
- SubQ, Oral
- SubQ, IM, Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 10 mg SC or IM daily
- Frequency
- Daily for 10–30 days
- Once daily
- Key Benefits
- Supports thymic epithelial cell function and T-cell maturation
- May partially restore thymic output reduced by age-related atrophy
- Normalizes T-lymphocyte subpopulation balance
- Supports immune recovery after illness, surgery, or chemotherapy
- Anti-aging effects on thymic tissue
- Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
- May improve vaccine responsiveness in older individuals
- Cardioprotective — protects cardiac tissue from ischemic damage
- Promotes cardiac regeneration and repair
- Improves vascular endothelium function
- Reduces atherosclerosis progression
- Anti-aging effect on heart muscle cells
- Improves cardiac output and exercise capacity
- Reduces oxidative stress in cardiovascular tissue
- May reduce arrhythmia frequency
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant immunological adverse events reported
- Excellent safety profile
- Mild injection site reactions
- Rare: transient hypotension
- Rare: mild arrhythmia at initiation in cardiac patients
- Stacks With
- —
- —